Paul Carlson PhD

Dr. Paul Carlson, is a principal investigator in the Laboratory of Mucosal Pathogens and Cellular Immunology, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, CBER, FDA. He received his Ph.D. from the University of Pittsburgh and performed postdoctoral research at the University of Michigan in the laboratory of Phil Hanna. Since starting his laboratory at FDA in 2015, Dr. Carlson’s research has focused on infections caused by the enteric pathogens Clostridium difficile and Vancomycin-resistant Enterococcus (VRE) species.

The laboratory has projects researching mechanisms of C. difficile pathogenesis, development of genetic tools to study C. difficile, host response to C. difficile, and bacteriophage therapy against VRE. His regulatory responsibilities include product review for fecal microbiota transplantation (FMT) and defined live biotherapeutic products as well as bacteriophage therapies.